• Text Resize A A A
  • Print Print
  • Share Share on facebook Share on twitter Share

Viral Hepatitis Blog

Hepatitis A
Lesson from hepatitis A outbreaks in 4 states: increasing vaccination among groups at risk might halt ongoing outbreaks and prevent future ones.
Tagged: Hepatitis A
Hepatitis C
Improving the HCV care cascade in the criminal justice system presents significant opportunities to impact both individual and community level HCV outcomes.
Tagged: Hepatitis C
Help shape the objectives for Healthy People 2030. Submit your comments today!
The U.S. Department of Health and Human Services (HHS) is soliciting written comments on the proposed objectives for Healthy People 2030 through January 17, 2019. This public comment period will allow comments on the proposed HP2030 objectives and members of the public can also propose their own objectives.
Posted in: Global Health
Ryan White 2018
Ryan White Program stakeholders invited to share ideas and recommendations for updates to 2 national strategies on December 11
NRV and NHAS callouts
Members of NASTAD recently shared recommendations for National Viral Hepatitis Action Plan and National HIV/AIDS Strategy beyond 2020.
NRV and NHAS callouts
ADM Brett Giroir, MD, Assistant Secretary for Health at HHS, initiated the process to develop the next editions of NVHAP and NHAS, both of which expire in 2020.
Hepatitis B
This blog showcases the work of several community partners in addressing the stigma and discrimination that can be associated with viral hepatitis
Tagged: Hepatitis B
Hepatitis C
To help optimize uptake of curative HCV treatment among people living with HIV, a decision tree helps healthcare providers navigate options to pay for treatment.
Tagged: Hepatitis C
CDC logo
The 7 indicators in CDC’s 2018 National Viral Hepatitis Progress Report provide a way to assess progress toward achieving key viral hepatitis goals.
Hepatitis B
The Food and Drug Administration (FDA) is an important federal partner in implementing the National Viral Hepatitis Action Plan and has just invited comment on important new guidance for industry in developing new drugs for hepatitis B virus (HBV) treatment. Please share this notice with colleagues in the field and consider submitting comments as we work toward developing improved treatments for HBV.
Tagged: Hepatitis B


  • of 40
  • >

Blog Archives